Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CME article

The Management of Pre-School Wheeze

Jayesh M. Bhatt1,*, Alan R. Smyth2,3
1 Consultant in Respiratory Paediatrics, Nottingham University Hospitals NHS Trust (QMC campus), Nottingham, NG7 2UH
2 Professor of Child Health, University of Nottingham Division of Child Health, Nottingham University Hospitals NHS Trust (QMC Campus), Nottingham NG7 2UH
3 Nottingham Respiratory Biomedical Research Unit

DEFINITIONS

Wheeze has been defined as a continuous high-pitched sound with a musical quality, emitting from the chest during expiration.1 Wheezing is a common symptom in pre-school children, with almost half of children having at least one episode of wheeze by the age of 6 years.2 Much progress has been made in classifying wheezing illness in older children and categorising it in terms of episodic (viral) wheeze and multiple-trigger wheeze. Diagnostic difficulties include other conditions that give rise to noisy breathing which could be misinterpreted as wheeze. Most preschool children with wheeze do not need rigorous investigations. Primary prevention is not possible but avoidance of environmental tobacco smoke exposure should be strongly encouraged. Bronchodilators provide symptomatic relief in acute wheezy episodes but the evidence for using oral steroids is conflicting for children presenting to the Emergency Department [ED]. Parent initiated oral steroid courses cannot be recommended. High dose inhaled corticosteroids [ICS] used intermittently are effective in children with frequent episodes of moderately severe episodic (viral) wheeze or multiple-trigger wheeze, but this associated with short term effects on growth and cannot be recommended as a routine. Maintenance treatment with low to moderate continuous ICS in pure episodic (viral) wheeze is ineffective. Whilst low to moderate dose regular ICS work in multi-trigger wheeze, the medication does not modify the natural history of the condition. Even if there is a successful trial of treatment with ICS, a break in treatment should be given to see if the symptoms have resolved or continuous therapy is still required. Maintenance as well as intermittent Montelukast has a role in both episodic and multi trigger wheeze. Good multidisciplinary support and education is essential in managing this common condition.

ARTICLE INFO

Keywords: Ruttles multi-trigger episodic viral wheeze inhaled corticosteroids Montelukast

SUMMARY

Wheeze, a common symptom in pre-school children, is a continuous high-pitched sound, with a musical quality, emitting from the chest during expiration. A pragmatic clinical classification is episodic (viral) wheeze and multiple-trigger wheeze. Diagnostic difficulties include other conditions that give rise to noisy breathing which could be misinterpreted as wheeze. Most preschool children with wheeze do not need rigorous investigations. Primary prevention is not possible but avoidance of environmental tobacco smoke exposure should be strongly encouraged. Bronchodilators provide symptomatic relief in acute wheezy episodes but the evidence for using oral steroids is conflicting for children presenting to the Emergency Department [ED]. Parent initiated oral steroid courses cannot be recommended. High dose inhaled corticosteroids [ICS] used intermittently are effective in children with frequent episodes of moderately severe episodic (viral) wheeze or multiple-trigger wheeze, but this associated with short term effects on growth and cannot be recommended as a routine. Maintenance treatment with low to moderate continuous ICS in pure episodic (viral) wheeze is ineffective. Whilst low to moderate dose regular ICS work in multi-trigger wheeze, the medication does not modify the natural history of the condition. Even if there is a successful trial of treatment with ICS, a break in treatment should be given to see if the symptoms have resolved or continuous therapy is still required. Maintenance as well as intermittent Montelukast has a role in both episodic and multi trigger wheeze. Good multidisciplinary support and education is essential in managing this common condition.
WHEN IS A WHEEZE NOT A WHEEZE?

Parents may ascribe a different meaning to the word “wheeze” to that understood by health professionals – leading to over-diagnosis of wheezing illness. Parents’ understanding of wheeze is often different from the definition used in epidemiological studies and many parents are better at locating sounds rather than labelling them. In a series of interviews, parents were first asked an open question, asking how they would describe their child’s noisy breathing, followed by specific questions asking them to select the medical terminology which they thought was the best description. Finally they were asked to select the sound closest to the noise made by their child, from a number of options. Over half of parents used the word wheeze initially but only one third were still using the term at the end of the interview - whereas the use of the word “rattle” doubled. Ruttle (also known as “rattle”) is lower in pitch with a rattling quality and lacking any musical features. Parents may be able to feel this noise as a vibration over the baby’s back. Ruttle may be related to excessive secretions or to abnormal tone in the larger airways. Wheeze and ruttle have quite distinct acoustic patterns.

Differential diagnosis

Airway resistance is inversely proportional to the fourth power of the radius of the airway (Poiseuille’s Law). It follows therefore that young children, who have smaller airways are much more likely to wheeze and that the prevalence of wheeze will fall off steeply as children get older and their airways radius increases. In young children, any inflammatory process, causing airway oedema, may narrow the airway, leading to wheeze. Children who have smaller airways, to start off with (for example infants of smoking mothers) are more vulnerable. It follows that wheezing is a common symptom in young children and has a wide differential diagnosis. Table 1 lists a number of differential diagnoses and the appropriate investigations. Most children with a characteristic history and examination findings in keeping with episodic (viral) wheeze or multiple-trigger wheeze do not need further investigations. Skin prick testing may identify triggers in multiple-trigger wheeze and help with allergen avoidance. Children should be investigated further if there are features in the history suggestive of other pathology, some of which have been listed in Table 1.

 MANAGEMENT

Primary prevention

Primary prevention of asthma is a highly desirable objective but, for practical reasons, can only be attempted in families where there is a strong history of atopy and the intervention may need to be commenced prenatally. Most interventions, assessed in randomised controlled trials, have assessed allergen avoidance – most commonly reducing exposure to house dust mite. These interventions achieve a reduction in house dust mite allergens in the child’s immediate environment, but not a reduction in symptoms of wheeze. A Cochrane review has concluded that.
reduction of exposure to single allergens, such as house dust mite, does not reduce the prevalence of physician diagnosed “asthma” in the under fives. However, reduction of exposure to multiple allergens in early life, including dietary and inhaled allergens, leads to a reduction in the prevalence of doctor diagnosed asthma in the under fives of around 30%. Environmental allergen reduction (e.g. occlusive bedding and mattresses) is expensive and dietary exclusion is inconvenient and intrusive. Therefore these interventions are only justified young infants at very high risk of asthma and with highly motivated parents (number needed to treat 17 per case prevented). Amongst the many reasons for encouraging women contemplating pregnancy to quit smoking, the strong association between pre-school wheeze and maternal smoking is one of the most compelling.

TREATING ACUTE WHEEZY EPISODES

Bronchodilators

When an infant presents with an acute episode of wheezing, it is important to distinguish episodic (viral) wheeze from bronchiolitis. A diagnostic approach is suggested in Table 1. It is important to make the distinction because bronchodilators produce at best a small and short lived benefit when given to infants with bronchiolitis. There are few randomised controlled trials of inhaled bronchodilators in pre-school children with wheeze. Conner randomised 29 children under 3 years to receive albuterol (salbutamol) or placebo for one week periods, during episodes of episodic (viral) wheeze, and showed an improvement in parent rated symptom score in the active group. Kraemer studied 36 wheezy infants, randomised to inhaled albuterol (salbutamol) or placebo and measured pulmonary function before and after the intervention. Significantly more infants in the active group showed improvement (as measured by thoracic gas volume and airway conductance). In contrast Chavasse et al. using a cross over design, randomised 80 wheezy infants under one year to salbutamol or placebo each administered three times daily for a period of 4 weeks. They found that salbutamol was not superior to placebo in terms of symptom control or lung function. However, the trial had a high attrition rate (48 infants completed the study) and employed a regimen of regular bronchodilator use for prolonged periods, which is now rarely used in clinical practice. Different regimens of bronchodilator administration have been compared in acutely wheezy children. A Cochrane review by Camargo et al. included 8 studies of intermittent vs. continuous (back to back) nebulisers but only one of these was restricted to children and this study enrolled children aged 2–18 years. The review finds benefit from continuous nebulisation, compared to intermittent nebulisers, but wisely advises caution in extrapolating the results to children – especially the very young. In contrast, the Cochrane review of bronchodilator administration by spacer vs. nebuliser includes 27 trials involving 2295 children – many more children than adults are included. Five of the trials were in pre-school children. In children, the use of a spacer (rather than a nebuliser) to administer a beta 2 agonist does not significantly reduce the risk of admission but does reduce the length of stay in the emergency department. With a spacer there were significantly fewer adverse effects, such as tachycardia.

The effects of adding an anticholinergic bronchodilator in children have been studied in a Cochrane review which included 13 trials (6 including children in the pre-school age group). Multiple doses of anticholinergic bronchodilators, such as ipratropium bromide, in addition to beta 2 agonists reduce admissions by 25% (number needed to treat = 12). In a further Cochrane review, Everard et al. studied the effects of adding an anticholinergic to a beta 2 agonist in wheezy children under two years and found that the combined group had improved symptom scores after 24 hours, compared to beta 2 agonist alone.

ORAL CORTICOSTEROIDS

Short courses (3–5 days) of oral corticosteroids are commonly administered to wheezy pre-school children both for episodic (viral) wheeze and multiple-trigger wheeze. However the evidence for this approach is conflicting. In a Cochrane review, which included children of all ages, Smith et al. studied randomised controlled trials of systemic steroids for hospitalised children with asthma. Four of seven eligible studies of oral steroids included some children in the pre-school age group. The review concludes that the use of oral steroids may allow more children to be discharged early (around 4 hours) and may lead to a shorter length of stay. The randomized controlled trials which have been restricted to the pre-school age group are summarized in Table 2. A randomised controlled trial by Csonka et al., published after the Cochrane review, studied children aged 6–35 months, with wheeze or breathing difficulty and symptoms of a viral infection. They randomised 230 children to...
### Table 2

Summary of double blind, placebo controlled, randomised controlled trials of oral steroids for preschool wheeze

| Study          | N     | Study population                  | Design           | Intervention                        | Duration | Findings                                                                 |
|----------------|-------|-----------------------------------|------------------|-------------------------------------|----------|--------------------------------------------------------------------------|
| Csonka 2003    | 230   | ED all pre-school                 | Parallel - 2 arm | Prednisolone 2 mg/kg/day            | 3 days   | Significantly fewer prednisolone patients needed additional asthma medication. Significantly shorter hospital stay. No reduction in hospitalisation. No difference in treatment failures between prednisolone & placebo. |
| Panickar 2009  | 687   | Hospitalised children             | Parallel - 2 arm | Prednisolone 5 days                 | 5 days   | No reduction in time to discharge. Children from each of the prednisolone & bud groups discharged significantly earlier. |
| Daugbjerg 1993 | 123   | Hospitalised children             | Parallel - 4 arm | Prednisolone & Terbutaline 2 mg/kg & bud groups alone | 1.5-18 mo | No difference in treatment failures between prednisolone & placebo. |
| Grant 1995     | 86    | ED / primary care                 | Crossover - 2 arm| Prednisolone vs. salbutamol         | 1 dose   | No reduction in outpatient visits or hospitalisation.  |
| Grant et al 2003| 233  | Hospitalised children             | Parallel - 2 arm | Prednisolone 20 mg/day              | 5 days   | No difference in symptoms score or hospital admissions. |

In studies which have been restricted to children under 2 years the findings have also been conflicting. Daugbjerg et al., in a four arm study of children aged up to 18 months, reported significantly earlier discharge in the group receiving prednisolone vs. terbutaline alone. In contrast, Fox et al. studied children aged 3-14 months in a randomised trial and found that prednisolone, given with oral salbutamol, produced no difference in treatment failures compared to placebo plus salbutamol.

Parents of children who suffer from episodic (viral) wheeze are frequently given oral prednisolone, to keep at home, and administer at the first sign of symptoms in an effort to truncate the attack. Is there any evidence to support this practice? Here the evidence is consistently negative. The effects of a single dose of oral prednisolone (2 mg/kg), administered by the parents of children aged 2-14 years at the first sign of wheezing, were studied by Grant et al. in a double blind, placebo controlled, crossover study. Follow up was for 12 months - 6months of prednisolone or 6months placebo. There was no benefit from prednisolone, in terms of number of outpatient visits, number of attacks or hospitalisations. In a large randomised controlled trial, Oommen and colleagues enrolled over 200 children aged 1-5 years during an episode of viral wheeze and advised the parents to administer study medication (prednisolone or placebo) during the next episode. Study medication was administered for 5 days and the outcome was the mean 7 day symptom score (day and night time symptoms). The children were stratified for eosinophil priming. There was no difference between steroid and placebo groups and no effect seen of eosinophil priming. The practice of giving parents a supply of oral prednisolone to administer to their children at the first sign of a wheezing episode cannot therefore be justified. A recent survey of physicians and parents suggested that such advice is still commonly given by doctors (though not always recalled by parents).

### INHALED CORTICOSTEROIDS

Episodic (viral) wheeze is characterised by intermittent symptoms and many parents would prefer it if inhaled corticosteroids (ICS) could be given intermittently rather than continuously, as is recommended for the treatment of asthma in older individuals. A Cochrane review of ICS for the treatment of episodic (viral) wheeze was published some years ago and further studies have since been conducted. Table 3 summarises the five high quality randomised controlled trials of the use of ICS (often in high doses) for the acute management of episodic (viral) wheeze in preschool children. The studies are listed in order of increasing total daily dose (given as beclomethasone equivalent). The studies which used less rigorous outcome measures (such as symptom score) were more likely to show benefit than those which used outcomes such as symptom free days. Older studies were less likely...
to measure and report adverse effects such as effects on height and early morning cortisol. When ICS are used in doses sufficient to reduce oral steroid use as in the study of Ducharme et al. (1500 mcg / day of fluticasone) then adverse effects on growth are clearly demonstrated. The authors advised against the use of this regimen in clinical practice. Based on the current evidence, it appears that intermittent high dose ICS are effective in children with frequent episodes of moderately severe episodic (viral) wheeze or multiple-trigger wheeze, but this associated with short term effects on growth and cannot be recommended as a routine.

**MAINTENANCE TREATMENT**

Maintenance treatment with low to moderate continuous ICS in pure episodic (viral) wheeze is ineffective as shown by Wilson et al. They compared Budesonide 400 mcg/day with placebo in preschool children given for a four month period and showed no significant difference in overall scores or number of symptom free days, acute episodes, or symptoms between episodes between the groups.

The situation for multiple-trigger wheeze is different and maintenance ICS have a role. Chavasse et al. showed improved mean daily symptom score and symptom free days in infants under 1 year, with recurrent wheeze, when treated with Fluticasone 150 mcg twice daily via spacer (compared to placebo) for 12 weeks. All infants had a personal or family history of atopy. Pao et al. showed that airway resistance measured by interrupter resistance (Rm) improves by 16% and bronchodilator responsiveness is reduced in pre school children who are skin prick test positive to one or more inhaled allergens when treated with inhaled Fluticasone 100 mcg twice daily via spacer for 6 weeks as compared to a placebo.

Maintenance treatment is effective while it is being used but not once it is discontinued. The episode-free days, number of exacerbations, or lung function are not significantly different in patients who have previously been randomised to fluticasone or placebo but have stopped treatment. Fluticasone (around 200 mcg/day), increases symptom free days, whilst reducing exacerbations and use of reliever medication, when commenced in children with a high asthma predicative index at around 1 year of age. However, in the same study, fluticasone did not prevent lung function decline or reduce airway reactivity at age 5 years. Furthermore fluticasone had a significant negative effect on the increase in height achieved by treated children (around 1 cm less than the placebo group at 2 years).

A trial of standard dose ICS trial is therefore a reasonable strategy in children with multiple-trigger wheeze but therapy is only effective while being taken and cannot alter the natural history of the disease. Treatment should only be continued after a successful trial and a break in treatment should be given to see if the symptoms have resolved or continuous therapy is still required.

**MONTELUKAST**

Continuous use

Montelukast is an anti-inflammatory medication – a leukotriene receptor antagonist (LTRA) - which is licensed for use in children from 6 months upwards with mild persistent asthma or exercise induced symptoms. Suitable formulations (granules) are available for pre-school children. The summary of product characteristics lists sleep disturbance, headache, abdominal pain and diarrhoea as adverse effects. However, the drug is generally well tolerated and long term treatment is an option, in contrast to oral steroid therapy.

In a 12 month multicenter, double-blind, parallel-group study of 2 to 5 year old children with episodic “asthma” exacerbations, associated with respiratory infections and minimal symptoms between episodes, oral montelukast, once daily for 12 months, was compared to placebo. Montelukast reduced the number of exacerbations by approximately 32% compared with placebo and the median time to first exacerbation was reduced by around 2 months.

Even when used for a shorter duration of 12 weeks, montelukast 4 mg once daily compared with placebo produces clinical benefit within 1 day of starting therapy in children aged 2 to 5 years. There is significant improvement in daytime and nighttime symptoms, the percentage of days with and without symptoms, the need for bronchodilators or oral corticosteroids and peripheral blood eosinophils.

**INTERMITTENT**

Montelukast has a rapid onset of action. Recently parent or caregiver initiated intermittent use of Montelukast therapy for 7 days or until symptoms had resolved for 48 hours in children aged 2-14 years resulted in clinically significant reductions in symptoms, primary care visits, emergency department attendances, number of days off from school or childcare (for the child) and days lost from work (for the parent or caregiver). However there was no significant effect on bronchodilator or oral prednisolone use.

Intermittent use of ICS and montelukast have shown some benefits, a recent randomised trial looked at head to head comparison of intermittent ICS, montelukast and placebo in children aged 12-59 months. The investigators randomised 238 children who had experienced at least two episodes of viral wheezing within the past year to receive either inhaled budesonide 1 mg twice daily; montelukast 4 mg once daily; placebo ICS; or placebo LTRA for 7 days. There was no significant effect of these therapies on episode free days over a one year period, but there was a statistically significant, albeit modest, reduction in symptom burden during respiratory tract illnesses. Also those children with a positive asthma predictive index or a greater illness severity (i.e. use of oral corticosteroids in the preceding year) had a greater

---

**Table 3**

Randomised controlled trials of inhaled corticosteroids used acutely for the management of episodic (viral wheeze)

| Study               | Inhaled corticosteroid | Duration (days) | Total daily dose (mcg) | Beclometasone equivalent | Benefit                                      | Harm           |
|---------------------|------------------------|-----------------|------------------------|--------------------------|---------------------------------------------|----------------|
| Bisgaard 2006       | Budesonide             | 14              | 400                    | 400                      | No difference in symptom free days          | No effect on height |
| Svedmyr 1999        | Budesonide             | 3               | 1600                   | 1600                     | Reduced symptom score                       | No effect on morning cortisol |
| Wilson 1990         | Budesonide             | 5               | 2250                   | 2250                     | Reduces symptom score                       | Not reported   |
| Ducharme 2005       | Fluticasone            | </> 10          | 1500                   | 3000                     | 50% reduction in oral steroid use           | Reduced height & weight velocity |
| Connelt 1993        | Budesonide             | </> 14          | 3200<sup>2</sup>       | 3200                     | Reduced symptom score                       | Not reported   |

1. Then budesonide 800 mcg daily for a further 7 days.
2. Children who were able to use the spacer device without a face mask were given 1600 mcg / day.
likelihood of experiencing a clinical benefit with these treatment strategies during episodic wheezing and both high dose ICS and Montelukast provided very similar effects.69

NONPHARMACOLOGIC MANAGEMENT

Environmental tobacco smoke exposure: As well as having a role in primary prevention,2 tobacco smoke exposure increases the risk of lower respiratory illness in young children (by 70% in the case of maternal smoking).70 Smoking amongst parents of young children should be firmly discouraged and smoking cessation interventions offered.

Education: An uncontrolled study has shown that parents of pre-school children who take part in an educational programme have improved asthma knowledge and self efficacy.71 In an RCT, using multiple teaching sessions led to an improvement in symptom free days for the child, less parenteral sleep disturbance and more accurate administration of asthma treatment by parents.72 One RCT has suggested that multi-session education sessions show greater benefit when the intervention is used with the parents of younger (1-3 years) rather than older pre-school children (4-6 years).73 In a randomised study, developmentally appropriate education targeted at pre school children themselves (rather than their parents) led to better knowledge, compliance and health.74 However another large RCT in preschool children with acute wheeze compared an education programme comprising two face to face sessions, written information and a written asthma action plan with usual care.75 There was no difference between groups in subsequent healthcare utilisation, disability score, parent’s quality of life and parental knowledge of asthma when assessed at 12 months. The more effective interventions appear to be those which are prolonged and intensive and this approach may be impractical in routine clinical care.

CONCLUSIONS

Effective management of pre-school children with episodic (viral) wheeze or multiple-trigger wheeze requires careful clinical assessment to rule out alternative diagnosis and a clear discussion with the child’s parents about the likely prognosis and the limitations of current treatment. Regular, careful re-evaluation of children’s symptoms is essential as the wheeze phenotype can change over time in pre-school children. Both high dose intermittent inhaled corticosteroids (1500 mcg/day of fluticasone for up to 10 days) and low dose long term maintenance (200 mcg/day of fluticasone) are associated with reduced health.76 Where inhaled steroids are used, they should be stopped if symptoms do not improve and treatment breaks should be employed. Montelukast offers some benefit in both episodic (viral) wheeze and multiple-trigger wheeze. Parent initiated courses of oral steroids are ineffective. Whatever treatment strategy is chosen, good multidisciplinary support and education is essential.

References

1. Brand FL, Baradari E, Biogard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008;32:1096–110.
2. Martinez FD, Wright AL, Tausig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med 1995;332:133–8.
3. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma (updated June 2009). Thorax 2008; 63 Suppl 4:i1–121. http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/sign/101%20revised%20june%202009.pdf.
4. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lemanske R, P. et al. GINA guidelines on asthma and beyond. Allergy 2007; 62:102–12.
5. Papadoopoulos NK, Kalobatsou A. Respiratory viruses in childhood asthma. Curr Opin Allergy Clin Immunol 2007; 7:51–6.
6. Evvard ML. Acute bronchiolitis and pneumonia in Infancy resulting from the respiratory syncytial virus. In: Tausig LM, Landau LI, editors. Pediatric Respiratory Medicine. Mosby; 2008.
7. Bont L, Alderen WM, Kimpen JL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000; 1:221–7.
8. Lemanske Jr RF, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol 2005;116:71–7.
9. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Tausig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541–5.
10. Schultz A, Devadas-sastry OE, Sly PD, Le S, Brand PL. The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr 2010;99:56–60.
11. Canes RS, Kanganathan SC, McKenzie SA. What do parents of wheezy children understand by “wheeze”? Arch Dis Child 2000; 81:327–32.
12. Canes RS, McKenzie SA. Parents’ interpretations of children’s respiratory symptoms on video. Arch Dis Child 2001;84:31–4.
13. Elphick HE, Sherlock P, Foxall G, Simpson EJ, Sheill NA, Primhak RA, et al. Survey of respiratory sounds in infants. Arch Dis Child 2001;86:535–9.
14. Elphick HE, Ritson S, Rodgers H, Everard ML, Elphick HE, Ritson S, et al. When a “wheeze” is not a wheeze: acoustic analysis of breath sounds in infants. Eur Respir J 2000;16:593–7.
15. Elphick HE, Ritson S, Everard ML. Differential response of wheezes and ruttles to anticholinergics. Arch Dis Child 2002;86:280–1.
16. Elphick HE, Lancaster GA, Solis A, Majumdar A, Gupta R, Smyth RL. Validity and reliability of acoustic analysis of respiratory sounds in infants. Arch Dis Child 2004;89:1059–63.
17. Lowe I, Murray CS, Martin L, Deas J, Cashin E, Poletti G, et al. Reported versus confirmed wheeze and lung function in early life. Arch Dis Child 2004;89:540–3.
18. Saglani S, McKenzie SA, Bush A, Payne DN. A video questionnaire identifies upper airway abnormalities in preschool children with reported wheeze. Arch Dis Child 2005;90:961–4.
19. Turner SW, Craig LC, Harbour PJ, Forbes SH, McNeill G, Seaton A, et al. Early raffles, purrs and whistles as predictors of later wheeze. Arch Dis Child 2008;93:701–4.
20. Mellis C. Respiratory noises: how useful are they clinically? Pediatr Clin North Am 2009;56:1–17.
21. Kuehl CE, Davis A, Brooke AM, Silverman M. Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet 2001;357:1821–5.
22. Stevens CA, Turner D, Kuehn CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J 2003;21:1000–6.
23. Martin ME, Grunstein MM, Larsen GL. The relationship of gastroesophageal reflux to nocturnal wheezing in children with asthma. Ann Allergy 1982;49:318–22.
24. Abdulmajid OA, Ebeid AM, Motaweh MM, Kleibo IS. Aspirated foreign bodies in the tracheobronchial tree: report of 250 cases. Thorax 1976;31:635–40.
25. Bush A, Chodhari R, Collins N, Copeland F, Hall P, Harcourt J, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007;92:1136–40.
26. Finder JD. Primary bronchomalacia in infants and children. J Pediatr 1997;130:59–66.
27. Yalcin E, Dogru D, Haliloglu M, Ozcelik U, Kiper N, Gocmen A. Postinfectious bronchiolitis obliterans in children: clinical and radiological profile and prognostic factors. Respiration 2003;70:371–5.
28. Saglani S, Nicholson AG, Scallan M, Balfour-Lynn I, Rosenthal M, Payne DN, et al. Investigation of young children with severe recurrent wheeze: any clinical benefit? Eur Respir J 2005;26:29–35.
29. Turato G, Barbato A, Baradari E, Zanin ME, Bazzan E, Loker-Oliani K, et al. Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma.[see comment]. J Am Pediatr Child Care Med 2008;138:476–82.
30. Ashad SH, Bateman B, Matthews SM. Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 2003;58:489–93.
31. Marks GB, Mihrsahi S, Kemp AS, Tovey ER, Webb K, Almqvist C, et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial.[see comment]. J Allergy Clin Immunol 2006;118:53–61.
32. Koopman LP, van Strien RT, Kerkhof M, Wijga A, Smit HA, de Jongste JC, et al. Placebo-controlled trial of house dust mite-impermeable mattress covers: effect on symptoms in early childhood. Am J Respir Crit Care Med 2002;166:307–13.
CME SECTION

This article has been accredited for CME learning by the European Board for Accreditation in Pneumology (EBAP). You can receive 1 CME credit by successfully answering these questions online.

(A) Visit the journal CME site at http://www.prjournals.com.

(B) Complete the answers online, and receive your final score upon completion of the test.

(C) Should you successfully complete the test, you may download your accreditation certificate (subject to an administrative charge).

Educational questions

Please answer as true or false.

1. Wheeze is a continuous high-pitched sound, without any musical quality, emanating from the chest during expiration.

2. The categories of pre-school wheeze according to its natural history as defined in epidemiological studies are: transient early; persistent; late onset.

3. The most common viral triggers for wheezing in children include: Rhinovirus, respiratory syncytial virus (RSV), rotavirus, human metapneumovirus, parainfluenza virus and adenovirus.

4. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, et al. Early oral prednisolone for preschool children with acute virus-induced wheezing.

5. Mass T, Kaper J, Sheikh A, Dompeling E, Wesseling G, et al. Reliable salbutamol inhaler and Aerochamber with mask.

6. Plotnick LD, Ducharme FM. Combined inhaled anticholinergics and beta2-agonists for acute asthma.

7. Smith M, Iqbal SMSI, Rowe B.H., N'Diaye T. Corticosteroids for hospitalised wheezy infants. Cochrane Database Syst Rev 2003; Issue 4. Art. No.: CD001115. DOI: 10.1002/14651858.CD001115.

8. Ho L, Landau LI, Le SPNL. Lack of efficacy of single-dose prednisolone in infants with acute asthma. Am Rev Respir Dis 1991; 144:347–51.

9. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Inhaled salbutamol for wheezy infants: a randomised controlled trial. Arch Dis Child 2008; 93:370–5.

10. Grant CC, Duggan AK, DeAngelis C. Independent parental administration of prednisolone in acute childhood asthma. Cochrane Database Syst Rev 2003; Issue 3. Art. No.: CD000286. DOI: 10.1002/14651858.CD000286.

11. Connell WT, Dolovich MB, Frame RA, Newhouse MT. Reliable salbutamol inhaler and Aerochamber with mask. Pediatr Pulmonol 1989; 6:263–7.

12. Kraemer R, Frey U, Sommer CW, Russi E. Short-term effect of albuterol, inhaled salbutamol, inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2005; 354:198–205.

13. Wilson NM, Silverman M, Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Archives of Disease in Childhood 1990; 65:407–10.

14. Connell G, Lenney W. Parental administration of inhaled salbutamol in infancy with oral salbutamol and prednisolone. Arch Dis Child 2003; 88:55–7.

15. Camargo CA, Spooner C, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Database Syst Rev 2003; Issue 4. Art. No.: CD001115. DOI: 10.1002/14651858.CD001115.

16. Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996; 3:1019–24.

17. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; Issue 2. Art. No.: CD000552. DOI: 10.1002/14651858.CD000552.pub2.

18. Plotnick LD, Ducharme F. Combined inhaled anticholinergics and beta2-agonists for children with acute asthma in the ED. Cochrane Database Syst Rev 2000; Issue 3. Art. No.: CD000606. DOI: 10.1002/14651858.CD000606.

19. Everard M, Bara A, Kurian M, Ducharme FM. Preemptive intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatrica 1999; 88:42–7.

20. Wilson NM, Silverman M, Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Archives of Disease in Childhood 1990; 65:407–10.

21. Connell G, Lenney W. Prevention of viral induced asthma attacks using inhaled budenoside. Arch Dis Child 1993; 68:85–7.

22. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic wheeze in preschool children. Arch Dis Child 1995; 72:317–20.

23. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone. Arch Dis Child 2001; 85:143–8.

24. Pao CS, McKenzie SA. Randomised controlled trial of fluticasone in preschool children with intermittent wheeze. Am J Respir Crit Care Med 2002; 166:945–9.

25. Murray CS, Woodcock C, MMJ, Morris J, Custovic A, IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754–62.

26. Bisgaard H, Zelen S, Garcia-Garcia ML, Johnston SL, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315–22.

27. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatr 2001; 108:186.

28. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175:323–5.

29. Bacharier LB, Phillips BR, Zeiger RS, Martinez FD, Lemanske Jr RF, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2006; 118:1127–35.

30. Strachan DP, Cook DG, Strachan DP, Cook DG. Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood. Thorax 1997; 52:905–14.

31. Mesters I, Meertens R, Kol G, Parcel GS. Effectiveness of a multidisciplinary education protocol in children with asthma (0-4 years) in primary health care. J Asthma 1994; 31:347–59.

32. Wilson SR, Latini D, Starf NJ, Fish L, Loes LM, Page A, et al. Education of parents of infants and very young children with asthma: a developmental evaluation of the Wheezy Web program. J Asthma 1996; 33:239–43.

33. Brown JV, Bakeman R, Celano MP, Demi AS, Kobrynski L, Wilson SR, et al. Home-based asthma education of young low-income children and their families. Journal of Pediatric Psychology 2002; 27:677–88.

34. Holzheuemer I, Mohay H, Masters IB. Educating young children about asthma: comparing the effectiveness of a developmentally appropriate asthma education video tape and picture book. Child Care Health Dev 1998; 24:85–99.

35. Stevens CA, Wesseldine LJ, Coutrel MJ, Dyer AJ, Osman LM, Silverman M, Parental education and guided self-management of asthma and wheezing in the pre-school child: a randomised controlled trial. Thorax 2002; 57:39–44.
4. Parents may ascribe a different meaning to the word “wheeze” to that understood by health professionals.
5. Many parents are better at locating sounds rather than labelling them.
6. Ruttle / “rattle” is a low pitch sound with a rattling quality and lacking any musical features.
7. As required bronchodilator treatment of acute wheezy episodes does not improve parent rated symptom score and some measures of lung function.
8. Adding an anticholinergic bronchodilator to a beta 2 agonist in wheezy children under two years is beneficial.
9. Oral prednisolone administered by the parents at the first sign of wheezing reduces number of outpatient visits, number of attacks and hospitalisations.
10. Oral prednisolone administered by parents improves symptom score in children who are eosinophil primed.
11. There is incontrovertible evidence that oral steroids in preschool wheezing children are ineffective.
12. Ruttles have distinct acoustic patterns as compared to wheeze when assessed objectively using acoustic analysis and are related to excessive secretions or to abnormal tone in the larger airways.
13. Atopic and non-atopic children with multiple-trigger wheeze have different findings on bronchoalveolar lavage and bronchial biopsy.
14. Inhaled corticosteroids for preschool wheeze affect growth when used in high doses intermittently.
15. High dose intermittent inhaled corticosteroids reduce oral steroid use in pre-school wheeze.
16. Maintenance treatment with low to moderate continuous ICS improve symptoms and reduce exacerbations in multi-trigger wheeze.
17. Maintenance inhaled corticosteroids modifies the natural history of pre school wheeze.
18. A successful treatment trial with inhaled corticosteroids justifies continuous therapy in multi-trigger wheeze.
19. Long term regular use of Montelukast reduces the number of exacerbations and prolongs the time to next exacerbation in episodic wheeze.
20. The clinical benefit with Montelukast is seen within a day of starting treatment.
21. Parent initiated intermittent use of Montelukast therapy for 7 days is an effective treatment option for preschool wheeze.
22. Intermittent Montelukast is better than high dose inhaled corticosteroids at reducing symptom burden during episodic wheezing.
23. Tobacco smoke exposure is important in both primary and secondary prevention of preschool wheeze.
24. Developmentally appropriate education targeted at pre school children themselves can improve outcomes and knowledge in these children.
25. Regular, careful re-evaluation of children’s symptoms is essential as the wheeze phenotype can change over time in pre-school children.